Legal Status
Legal Status
Notice
Government-Owned Invention; Availability for Licensing: “Therapeutic Method to Treat Cancer and Define Cellular Regulatory Processes-Transcription Factor Decoy and Tumor Growth Factor”
A Notice by the National Institutes of Health on
Document Details
Information about this document as published in the Federal Register.
- Printed version:
- Publication Date:
- 04/03/2000
- Agencies:
- National Institutes of Health
- Document Type:
- Notice
- Document Citation:
- 65 FR 17514
- Page:
- 17514 (1 page)
- Document Number:
- 00-8106
Document Details
-
Enhanced Content - Table of Contents
This tables of contents is a navigational tool, processed from the headings within the legal text of Federal Register documents. This repetition of headings to form internal navigation links has no substantive legal effect.
Enhanced Content - Table of Contents
-
Enhanced Content - Submit Public Comment
- This feature is not available for this document.
Enhanced Content - Submit Public Comment
-
Enhanced Content - Read Public Comments
- This feature is not available for this document.
Enhanced Content - Read Public Comments
-
Enhanced Content - Sharing
- Shorter Document URL
- https://www.federalregister.gov/d/00-8106 https://www.federalregister.gov/d/00-8106
Enhanced Content - Sharing
-
Enhanced Content - Document Tools
These tools are designed to help you understand the official document better and aid in comparing the online edition to the print edition.
-
These markup elements allow the user to see how the document follows the Document Drafting Handbook that agencies use to create their documents. These can be useful for better understanding how a document is structured but are not part of the published document itself.
Display Non-Printed Markup Elements
Enhanced Content - Document Tools
-
-
Enhanced Content - Developer Tools
This document is available in the following developer friendly formats:
- JSON: Normalized attributes and metadata
- XML: Original full text XML
- MODS: Government Publishing Office metadata
More information and documentation can be found in our developer tools pages.
Enhanced Content - Developer Tools
Published Document
This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.
AGENCY:
National Institutes of Health, Public Health Service, DHHS.
ACTION:
Notice.
SUMMARY:
The invention listed below is owned by an agency of the U.S. Government and is available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally funded research and development.
ADDRESSES:
Licensing information and a copy of the U.S. patent application referenced below may be obtained by contacting J. R. Dixon, Ph.D., at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804 (telephone 301/496-7056 ext 206; fax 301/402-0220; E-Mail: jd212g@NIH.GOV). A signed Confidential Disclosure Agreement is required to receive a copy of any patent application.
End Preamble Start Supplemental InformationSUPPLEMENTARY INFORMATION:
Invention Title: “Transcription Factor Decoy and Tumor Growth Inhibitor”.
Inventors: Dr. Yoon S. Cho-Chung (NCI).
USPA SN: 08/977,643 [= DHHS Ref. No. E-192-97/0]—Filed with the U.S.P.T.O. on November 24, 1997.
Technology: Alteration of gene transcription by inhibition of specific transcriptional regulatory proteins has important therapeutic potential. Synthetic double-stranded phosphorothioate oligonucleotides with high affinity for a target transcription factor can be introduced into cells as decoy cis-elements to bind the factors and alter gene expression. The CRE (cyclic AMP response element)-transcription factor complex is a pleiotropic activator that participates in the induction of a wide variety of cellular and viral genes. Because the CRE cis-element, TGACGTCA, is palindromic, a synthetic single-stranded oligonucleotide composed of the CRE sequence self-hybridizes to form a duplex/hairpin. The CRE-palindromic oligonucleotide can penetrate into cells, compete with CRE enhancers for binding transcription factors, and specifically interfere with CRE- and AP-1-directed transcription in vivo. These oligonucleotides restrained tumor cell proliferation, without affecting the growth of noncancerous cells. This decoy oligonucleotide approach offers great promise as a tool for defining cellular regulatory processes and treating cancer and other diseases. [see J. Biol. Chem. 274, 1573-1580 (1999); online at http://www.jbc.org/]
The above mentioned Invention is available, including any available foreign intellectual property rights, for licensing.
Start SignatureDated: March 24, 2000.
Jack Spiegel,
Director, Division of Technology Development & Transfer, Office of Technology Transfer
[FR Doc. 00-8106 Filed 3-31-00; 8:45 am]
BILLING CODE 4140-01-P